Grant awardees from the Arizona Biomedical Research Centre, Flinn Foundation and the Valley Research Partnership will present their research during the Sixth Annual ABRC-Flinn Research Conference.
The event is open to the public, and researchers and healthcare professionals are encouraged to attend. We also welcome students, educators and the general public to attend this valuable conference. Early registration is encouraged.
This virtual conference will feature keynote speaker Chris Glembotski, PhD, featured speaker Jessica Langbaum, PhD, and grant awardees from the Arizona Biomedical Research Centre, Flinn Foundation and the Valley Research Partnership present their research.
Keynote speaker, Dr. Glembotski, will present at 9 a.m., and the featured speaker, Dr. Langbaum, will present at 3:15 p.m.
Christopher Glembotski, PhD, is a renowned researcher in cardiovascular disease with a remarkable background and a wide-range of accomplishments not only as a scientist, but as an educator and leader. He is the inaugural director of the Translational Cardiovascular Research Center; the associate dean for Research; and a professor in the Department of Internal Medicine.
Prior to joining the college, Dr. Glembotski served as the director of the San Diego State University (SDSU) Heart Institute and was a distinguished professor of biology. Dr. Glembotski has an extensive research background and garnered more than $35 million in grants during his time at SDSU. Since he started his own lab in 1983, he has been continuously funded by the National Institutes of Health.
His research centers around the area of molecular cardiology, with a focus on identifying new therapeutics for treating ischemic and hypertrophic cardiomyopathies.
Along with colleagues Pierre Tariot, MD and Eric Reiman, MD, Dr. Langbaum leads the Alzheimer’s Prevention Initiative, which is credited with helping launch a new era in Alzheimer’s prevention research. Dr. Langbaum is director of the Alzheimer’s Prevention Registry and its GeneMatch program. Her research is focused on:
- Establishing the science of participant recruitment and retention for Alzheimer’s prevention studies studies, including designing and executing participant recruitment registries.
- Assessing the impact of genetic testing and risk disclosure, in particular disclosure of APOE and other biomarker (e.g., brain amyloid) results, and
- Designing and executing preclinical AD treatment studies, including developing sensitive, novel composite cognitive test scores for use as primary endpoint measures.